GNRSU Stock Crashes 99.99% on May 1, 2026 – Greenrose Holdings Plummets

GNRSU stock has experienced a catastrophic collapse, dropping 99.99% to just $0.000001 per share as of May 1, 2026. The Greenrose Holding Company Inc., a healthcare sector cannabis producer based in Amityville, New York, now trades on the OTC Pink Markets (PNK) with a market capitalization of only $13. This extreme decline represents one of the most severe stock deteriorations in recent market history. The company, which went public in February 2020, has seen its valuation evaporate almost entirely. Trading volume remains minimal at just 145 shares, reflecting the stock’s distressed status. Investors holding GNRSU stock face an unprecedented situation requiring immediate attention and reassessment of their positions.

GNRSU Stock Price Collapse and Market Conditions

The GNRSU stock price has reached penny stock territory at $0.000001 USD, down from a previous close of $0.15. This represents a staggering loss of $0.149999 per share in a single trading session. The stock’s year-high stands at $0.151, while the year-low matches the current price at $0.000001, indicating sustained downward pressure throughout the period.

Trading activity remains extremely thin with only 145 shares exchanged on May 1, 2026. The 50-day and 200-day moving averages both sit at $0.15, suggesting the stock has fallen dramatically below its recent trading range. With a market cap of just $13 and 12.85 million shares outstanding, GNRSU stock now trades at valuations that raise serious questions about the company’s viability and investor confidence.

Financial Metrics and Valuation Analysis

Despite the stock’s collapse, GNRSU’s financial metrics reveal a complex picture. The company reports an EPS of 3.097 and a PE ratio of 0.00000032, which appears artificially low due to the microscopic stock price. Revenue per share stands at $1.58, while net income per share reaches $1.12, suggesting operational profitability on a per-share basis.

However, liquidity concerns dominate the analysis. The current ratio of 0.21 indicates the company has only $0.21 in current assets for every $1.00 of current liabilities. Working capital is deeply negative at -$103.4 million, and tangible asset value sits at -$116.3 million. These metrics signal severe financial distress. The debt-to-equity ratio of 1.57 shows the company carries substantial leverage relative to shareholder equity. Meyka AI rates GNRSU with a grade of B with a HOLD suggestion, factoring in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors.

Market Sentiment and Trading Activity

Trading Activity remains critically depressed for GNRSU stock. Volume of just 145 shares on May 1, 2026 reflects minimal investor interest and severe liquidity constraints. The stock’s presence on the OTC Pink Markets (PNK) rather than a major exchange compounds accessibility issues for retail investors seeking to exit positions.

Liquidation Pressure appears evident from the stock’s catastrophic decline. The 99.99% loss suggests forced selling, margin calls, or fundamental business deterioration. With such minimal trading volume, any attempt to liquidate larger positions would face extreme difficulty finding buyers. The stock’s distressed status on the pink sheets indicates it no longer meets listing standards for major exchanges. Track GNRSU on Meyka for real-time updates on this deteriorating situation.

Greenrose Holdings Business Operations and Outlook

The Greenrose Holding Company Inc. operates in the healthcare sector as a drug manufacturer specializing in medical cannabis products. Headquartered in Amityville, New York, the company employs 910 full-time workers and engages in cultivating, processing, and packaging cannabis derivatives. Founded in 2014, the company went public in February 2020 with initial market enthusiasm.

The company’s operational metrics show mixed signals. Gross profit margin of 59.05% and net profit margin of 70.59% suggest strong unit economics on products sold. However, inventory turnover of just 0.83 indicates slow-moving inventory, with 439 days of inventory on hand. This suggests either weak demand or inventory obsolescence issues. The cannabis industry’s regulatory challenges and competitive pressures may be contributing factors to GNRSU’s market collapse. CEO Nicole Conboy leads operations from the company’s Broadway office location.

Final Thoughts

GNRSU stock has collapsed to $0.000001 per share, indicating severe financial distress. The company faces negative working capital of $103.4 million, minimal trading volume, and a $13 market cap. Despite adequate gross margins, critical liquidity constraints and debt burdens have destroyed shareholder value. The stock’s migration to OTC pink sheets reflects failure to maintain listing standards. Investors should seek professional advice immediately and recognize the extreme risks of penny stocks.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.